Novo Nordisk 2026 Sales Drop Expected Due to Competition

Novo Nordisk's 2026 profit outlook is down 5-13%, a big change from its 2025 growth. This is because of lower drug prices and more companies selling similar weight loss medicines.
By Newsroom | Business, Health |

Financial Performance Signals Change

Novo Nordisk has released its financial report for 2025, indicating solid full-year sales growth of over 10% at constant exchange rates, with operating profits up 6%. This performance lands within previously stated guidance ranges, with net sales reaching $43.27 billion and operating profit totaling $17.88 billion at constant exchange rates. However, reported figures in U.S. dollars show a 1% decline in operating profit. This dip is attributed to currency fluctuations and approximately $1.12 billion in costs associated with a company-wide transformation program.

The company's 2026 outlook reveals a significant shift, projecting a decline in both sales and operating profit between 5% and 13% at constant exchange rates. This adjustment reflects mounting pricing pressures, transformation expenses, and the intensifying competition within the global GLP-1 market. Specifically, management points to more pronounced pressures expected in 2026, particularly in the U.S., due to lower realized prices, Medicaid coverage reductions for obesity treatments, and the "Most Favored Nations" pricing agreement.

Read More: US Pauses Hormuz Operation, Oil Prices Fall

Strategic Moves and Market Pressures

In response to a dynamic market, Novo Nordisk is implementing strategic adjustments. Prices for its blockbuster obesity drug Wegovy and diabetes treatment Ozempic saw reductions in the first quarter of 2024. This recalibration comes amid increased sales volumes and heightened competition. The company is also actively working to bolster its manufacturing capabilities, with parent company Novo Holdings set to acquire Catalent, a key manufacturing subcontractor, and subsequently sell three fill-finish sites to Novo Nordisk upon deal completion.

Global Expansion and Competitive Landscape

Wegovy's market presence continues to expand, with recent launches in Spain and upcoming introductions in Canada. These expansions aim to broaden access, bringing the total number of markets where the drug is available to eleven. The company reports that approximately 27,000 new patients in the U.S. are initiating treatment with the weekly injection each week.

Read More: Trump says he passed cognitive test 3 times

Novo Nordisk slightly raises outlook as first-quarter profit beats forecast - 1

However, the rise of alternative treatments and compounded versions of weight-loss drugs is impacting Novo Nordisk's U.S. market share. While the company anticipates a potential easing of these "copycat" sales, it has also signaled its intent to pursue companies unlawfully distributing such alternatives. This competitive pressure, coupled with disappointing trial results for its next-generation obesity drug candidate CagriSema, has contributed to market sentiment.

Financial Projections and Analyst Sentiment

Novo Nordisk has raised its sales and operating profit outlook for 2023, citing accelerated volume growth for its GLP-1 treatments, particularly Ozempic in the U.S. Looking further ahead, the company has released its 2026 sales and operating profit outlook, alongside initiating a new $2.1 billion share repurchase program for 2026. This program is designed to reduce share capital and manage obligations from share-based incentive plans.

Despite past successes, recent analyst sentiment suggests a cautious approach. The consensus recommendation for Novo Nordisk (NVO) stock is currently "Hold," with an average 12-month price target around $43.00 to $51.00, forecasting a potential increase in stock price.

Read More: Oil Prices Drop After Strait of Hormuz Declared Open

Corporate Structure and Background

Novo Nordisk, headquartered in Bagsværd, Denmark, is a global pharmaceutical company recognized for its expertise in diabetes care and metabolic health. Its core product lines encompass a range of diabetes therapies, including insulins and incretin-based treatments, alongside treatments for hemophilia, growth disorders, and hormone replacement. Research and development remain central to its strategy, with ongoing investment in next-generation medicines for metabolic, cardiovascular, and rare diseases. The company's B shares are listed on both the Nasdaq Copenhagen and the New York Stock Exchange (NYSE) as American Depository Receipts (ADRs).

Frequently Asked Questions

Q: Why does Novo Nordisk expect sales and profits to fall in 2026?
Novo Nordisk predicts a 5% to 13% drop in sales and profits in 2026. This is because of lower prices for their drugs, higher costs from a company change, and more competition for weight loss medicines.
Q: What is happening with Wegovy and Ozempic prices?
The prices for Wegovy and Ozempic were lowered in early 2024. This is happening because of less favorable government drug pricing rules in the U.S. and more companies selling similar drugs.
Q: How is Novo Nordisk trying to get more manufacturing done?
Novo Nordisk's parent company, Novo Holdings, is buying Catalent, a company that makes their drugs. After buying Catalent, three factories will be sold to Novo Nordisk to help make more medicines.
Q: What is the competition like for Novo Nordisk's weight loss drugs?
There are more alternative treatments and similar drugs being sold. This is affecting Novo Nordisk's share of the market in the U.S. The company is also taking legal action against some companies selling similar drugs without permission.
Q: What are analysts saying about Novo Nordisk's stock?
Analysts currently suggest holding Novo Nordisk stock. The average price target for the next year is between $43.00 and $51.00, suggesting the stock price might go up.